title: What are the precautions with proton pump inhibitor use for reflux disease?
abstract: Gastroesophageal reflux disease (GERD) affects 10% to 20% of the western world's population. Current treatment guidelines recommend proton pump inhibitors (PPIs) as first-line therapy. Although PPIs cause mild adverse reactions, they pose risks, particularly for older adults with comorbidities.
authors.affiliation: Cortney M. Mospan is an assistant professor of pharmacy practice at East Tennessee State University's Bill Gatton College of Pharmacy in Johnson City, Tenn. She also serves as a clinical pharmacist with the university's charitable pharmacy. The author has disclosed no potential conflicts of interest, financial or otherwise.
authors.forename: Cortney M
authors.initials: CM
authors.lastname: Mospan
mesh_terms: D018798:Anemia, Iron-Deficiency / Q000453:epidemiology; D000077144:Clopidogrel; D017714:Community-Acquired Infections / Q000453:epidemiology*; D003677:Deficiency Diseases / Q000453:epidemiology*; D004347:Drug Interactions; D004761:Enterocolitis, Pseudomembranous / Q000453:epidemiology*; D050723:Fractures, Bone / Q000453:epidemiology*; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D008275:Magnesium Deficiency / Q000453:epidemiology; D011014:Pneumonia / Q000453:epidemiology*; D054328:Proton Pump Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives; D014806:Vitamin B 12 Deficiency / Q000453:epidemiology
chemical_list: D054328:Proton Pump Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine